Suzhou Yikesai Biotechnology Co., Ltd
Suzhou Yikesai Biotechnology Co., Ltd., with the mission of "accelerating the application of life sciences and benefiting people's health", is committed to solving the bottleneck of biopharmaceuticals and achieving the localization of key raw materials. It has become one of the excellent enterprises in the upstream core raw materials of biopharmaceuticals in China. The company is a national high-tech enterprise, a national specialized and innovative small giant enterprise, a member of the China International Serum Industry Association (ISIA), and a research center for CD serum-free culture medium engineering in the fields of biopharmaceuticals and cell therapy in Jiangsu Province.
The company currently focuses on three major product segments: serum-free culture media, fetal bovine serum, and identification reagents, providing international quality products and services for customers in biopharmaceuticals, cell and gene therapy, and basic scientific research. The company relies on an international and specialized R&D technology team, quality and production team, and commercialization team to continuously innovate and pursue excellence. While continuously optimizing product performance, it ensures reliable quality and stable supply, fully empowering the rapid and healthy development of the biopharmaceutical industry, and creating cell culture "Chinese chip" products.
Recommended Posts
-
Cancer cells are very "cunning", they will use immune checkpoints to conceal their "bad person identity" - the proteins expressed on the surface of tumor cells will bind to the proteins on the surface of T cells, sending a signal to the immune system to "own people, don't kill me", thus avoiding the detection and attack of immune cells.Based on this principle, scientists have developed antibodies that block binding, namely immune checkpoint inhibitors, to achieve anti-cancer goals by releasing T cells. So far, the FDA has approved six immune checkpoint inhibitors targeting pathways, suitable for various cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma. -
Researchers have found that their appendix tissue has protein clusters similar to those observed in the brains of Parkinson's disease patients. This discovery suggests that the appendix plays a role in the early stages of this disease by aggregating these same proteins. These proteins contribute to Parkinson's disease in some way, so appendectomy may prevent their harmful activity. Researchers have found that their appendix tissue has protein clusters similar to those observed in the brains of Parkinson's disease patients. This discovery suggests that the appendix plays a role in the early stages of this disease by aggregating these same proteins. These proteins contribute to Parkinson's disease in some way, so appendectomy may prevent their harmful activity.
-
Under the trend of domestic substitution in the medical device industry, the drive to explore overseas markets is also increasing. Going global is the key for the medical device industry to seek new growth curves and enhance international competitiveness.Moreover, China is implementing a more proactive opening-up strategy. Jointly building the "the Belt and Road" has become a popular international public product and international cooperation platform to achieve higher quality and deeper mutual benefit and win-win results with countries along the line.
